Novel strategies for immuno-oncology breakthroughs with cell therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel strategies for immuno-oncology breakthroughs with cell therapy
Authors
Keywords
-
Journal
Biomarker Research
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-31
DOI
10.1186/s40364-021-00316-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia
- (2020) Junfang Yang et al. BLOOD
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
- (2020) Chongxian Pan et al. Journal of Hematology & Oncology
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering CAR-T Cells for Next-Generation Cancer Therapy
- (2020) Mihe Hong et al. CANCER CELL
- Recent advances in CAR-T cell engineering
- (2020) Ruihao Huang et al. Journal of Hematology & Oncology
- Emerging therapies in mantle cell lymphoma
- (2020) Walter Hanel et al. Journal of Hematology & Oncology
- Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
- (2020) Yuru Nie et al. Biomarker Research
- Biomarkers in individualized management of chimeric antigen receptor T cell therapy
- (2020) Mengyi Du et al. Biomarker Research
- BCMA-targeted immunotherapy for multiple myeloma
- (2020) Bo Yu et al. Journal of Hematology & Oncology
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade
- (2020) Shivani Srivastava et al. CANCER CELL
- STING agonist promotes CAR T cell trafficking and persistence in breast cancer
- (2020) Nuo Xu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
- (2020) Ahmet Yilmaz et al. Journal of Hematology & Oncology
- Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
- (2020) Sri Krishna et al. SCIENCE
- Engineering better chimeric antigen receptor T cells
- (2020) Hao Zhang et al. Experimental Hematology & Oncology
- The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review
- (2019) Jianxiang Zhang et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells
- (2019) Esther Drent et al. CLINICAL CANCER RESEARCH
- Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.
- (2019) Prasad S. Adusumilli et al. JOURNAL OF CLINICAL ONCOLOGY
- T-cell receptor and chimeric antigen receptor in solid cancers
- (2019) Alexander A. Azizi et al. CURRENT OPINION IN ONCOLOGY
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy
- (2019) Qianqian Gao et al. Cancer Medicine
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
- (2019) Akintunde Akinleye et al. Journal of Hematology & Oncology
- TCR-like antibodies in cancer immunotherapy
- (2019) Qinghua He et al. Journal of Hematology & Oncology
- Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
- (2019) Rachel Grosser et al. CANCER CELL
- Chimeric antigen receptor T cell therapies for multiple myeloma
- (2019) Chao Wu et al. Journal of Hematology & Oncology
- Recent updates on CAR T clinical trials for multiple myeloma
- (2019) Quande Lin et al. Molecular Cancer
- CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
- (2019) Bryan D. Choi et al. Journal for ImmunoTherapy of Cancer
- Targeting cancers through TCR-peptide/MHC interactions
- (2019) Qinghua He et al. Journal of Hematology & Oncology
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
- (2018) Miriam Y. Kim et al. CELL
- Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
- (2018) Shivani Srivastava et al. JOURNAL OF IMMUNOLOGY
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Gene therapy comes of age
- (2018) Cynthia E. Dunbar et al. SCIENCE
- CRISPR-Cas guides the future of genetic engineering
- (2018) Gavin J. Knott et al. SCIENCE
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
- (2017) Chiun Hsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
- (2017) Sanja Stevanović et al. SCIENCE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues
- (2016) Ashwini Balakrishnan et al. CLINICAL CANCER RESEARCH
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma
- (2015) Kyuichi Kadota et al. Journal of Thoracic Oncology
- AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
- (2015) D. S. Pereira et al. MOLECULAR CANCER THERAPEUTICS
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
- (2015) A. Morello et al. Cancer Discovery
- The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
- (2015) Hideki Ujiie et al. OncoImmunology
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- The BAFF/APRIL system in SLE pathogenesis
- (2014) Fabien B. Vincent et al. Nature Reviews Rheumatology
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells
- (2014) C. Berger et al. Cancer Immunology Research
- A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies
- (2013) J. Deckert et al. BLOOD
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
- (2013) Paul F Robbins et al. NATURE MEDICINE
- Clinical Impact of Immune Microenvironment in Stage I Lung Adenocarcinoma: Tumor Interleukin-12 Receptor β2 (IL-12Rβ2), IL-7R, and Stromal FoxP3/CD3 Ratio Are Independent Predictors of Recurrence
- (2012) Kei Suzuki et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
- (2010) J. N. Kochenderfer et al. BLOOD
- Adoptive cell therapy for the treatment of patients with metastatic melanoma
- (2009) Steven A Rosenberg et al. CURRENT OPINION IN IMMUNOLOGY
- Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization
- (2009) Hui K. Gan et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started